● 72420 Access ● # _____

Search Request Form

Scientific and Technical Information Center

Requester's Full Name: L. Eric Crane Examiner #: 65753 Date: **08/01/02**
Art Unit: 1623 Phone Number: **308-4639** Serial No. **09/640,530.**
Mail Box & Bldg/Room Loc: 8D-14/CM-1 Results Format Preferred: **PAPER [8B-19/CM-1]**

If more than one search is submitted, please prioritize searches in order of need.

****

Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched. Include the elected species or structures, key words, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc., if known. Please attach a copy of the cover sheet, pertinent claims, and/or abstract..

Title of Invention: See attached copy of claims.
Inventors (please provide full names): See attached copy of claims.
Earliest Priority Filing Date: **09/30/99**

For Sequence Searches only ***Please include all of the pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.***

Please search for the compounds of claim 1; see claim 101 for specific embodiments.
Please also search for methods of reducing tissue damage resulting from ischemia or hypoxia by administration of a compound of claim 1 to a host in need thereof.
Please also search for methods of making the compounds of claim 1.
Elected Claims: 1-29, 41-81 and 101.

****

STAFF USE ONLY

Searcher: Jan
Searcher Phone #: 4498
Searcher Location: _____
Date Searcher Picked Up: 8/7/02
Date Completed: 8/7/02
Searcher Prep & Review Time: _____
Clerical Prep Time: 25
Online Time: 45

Type of Search

NA Sequence(#) _____
AA Sequence(#) _____
Structure (#) ✓
Bibliographic _____
Litigation _____
Full Text _____
Patent Family _____
Other _____

Vendors/cost as applicable

STN ✓
Dialog _____
Questel/Orbit _____
Dr. Link _____
Lexis/Nexis _____
Seq.Syst'ms _____
WWW/Internet _____
Other(Specify) _____

PTO-1590 (8-2001)

Jan Delaval
Reference Librarian
Biotechnology & Chemical Library
CM1 1E07 – 703-308-4498
jan.delaval@uspto.gov

```
=> fil reg
FILE 'REGISTRY' ENTERED AT 15:39:22 ON 07 AUG 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2002 American Chemical Society (ACS)

STRUCTURE FILE UPDATES:    5 AUG 2002  HIGHEST RN 442625-99-2
DICTIONARY FILE UPDATES:   5 AUG 2002  HIGHEST RN 442625-99-2

TSCA INFORMATION NOW CURRENT THROUGH January 7, 2002

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

Crossover limits have been increased.  See HELP CROSSOVER for details.

Calculated physical property data is now available.  See HELP PROPERTIES
for more information.  See STNote 27, Searching Properties in the CAS
Registry File, for complete details:
http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf

=> d sta que l15
L6                STR
```




```
VAR G1=O/C/S
VAR G2=C/N
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS  24

STEREO ATTRIBUTES: NONE
L8           267 SEA FILE=REGISTRY SSS FUL L6
L9               STR
```

Jan Delaval
Reference Librarian
Biotechnology & Chemical Library
CM1 1E07 – 703-308-4498
jan.delaval@uspto.gov



VAR G1=O/C/S
VAR G2=C/N
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 24

STEREO ATTRIBUTES: NONE
L10 142 SEA FILE=REGISTRY SUB=L8 SSS FUL L9
L11 STR



VAR G1=O/C/S
VAR G2=C/N

```
VAR G3=O/S/N
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS  25

STEREO ATTRIBUTES: NONE
L12         137 SEA FILE=REGISTRY SUB=L10 SSS FUL L11
L13           5 SEA FILE=REGISTRY ABB=ON  PLU=ON  L10 NOT L12
L14           2 SEA FILE=REGISTRY ABB=ON  PLU=ON  L13 AND (C17H20N6O3 OR
                C17H19IN6O3)
L15         139 SEA FILE=REGISTRY ABB=ON  PLU=ON  (L12 OR L14)


=> d his l15-

     (FILE 'REGISTRY' ENTERED AT 15:25:13 ON 07 AUG 2002)
L15         139 S L12,L14

     FILE 'HCAOLD' ENTERED AT 15:34:01 ON 07 AUG 2002
L16           5 S L15

     FILE 'HCAPLUS' ENTERED AT 15:34:13 ON 07 AUG 2002
L17           2 S L15
L18           1 S L17 AND (DENINNO M? OR DE NINNO M? OR
L19           1 S L17 AND PFIZER?/PA,CS
L20           2 S L17-L19

     FILE 'USPATFULL, USPAT2' ENTERED AT 15:36:32 ON 0
L21           0 S L15

     FILE 'REGISTRY' ENTERED AT 15:36:45 ON 07 AUG 2002
L22           1 S L15 AND CAOLD/LC

     FILE 'HCAOLD' ENTERED AT 15:36:58 ON 07 AUG 2002
               SEL AN L16 1-5
               EDIT /AN /OREF

     FILE 'HCAPLUS' ENTERED AT 15:37:33 ON 07 AUG 2002
L23           8 S E1-E5
L24           5 S L23 NOT (YOSHID ? OR CASTELLANI ? OR ANGIER ?)/AU

     FILE 'REGISTRY' ENTERED AT 15:39:22 ON 07 AUG 2002

=> d ide can l22

L22  ANSWER 1 OF 1  REGISTRY  COPYRIGHT 2002 ACS
RN   98177-71-0  REGISTRY
CN   Adenosine, 3'-amino-N-benzyl-3'-deoxy- (6CI, 7CI)  (CA INDEX NAME)
FS   STEREOSEARCH
MF   C17 H20 N6 O3
SR   CAOLD
LC   STN Files:   BEILSTEIN*, CAOLD
        (*File contains numerically searchable property data)

Absolute stereochemistry.
```

These are the only refs for these compounds?



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

5 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

=> fil hcaold
FILE 'HCAOLD' ENTERED AT 15:39:37 ON 07 AUG 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

PRE-1967 CHEMICAL ABSTRACTS FILE WITH HOUR-BASED PRICING
FILE COVERS 1907-1966
FILE LAST UPDATED: 01 May 1997 (19970501/UP)

This file contains CAS Registry Numbers for easy and accurate substance identification. Title keywords, authors, patent assignees, and patent information, e.g., patent numbers, are now searchable from 1907-1966. TIFF images of CA abstracts printed between 1907-1966 are available in the PAGE display formats.

This file supports REG1stRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

=> d all hitstr tot l16

L16 ANSWER 1 OF 5 HCAOLD COPYRIGHT 2002 ACS
AN CA59:5251g CAOLD
TI synthesis and reactions of 3'-amino-3'-deoxyribosides of 6-chloropurine
AU Goldman, Leon; Marsico, J. W.
IT 72-94-6 6044-48-0 14125-61-2 34522-42-4 36043-68-2 38228-99-8
71528-47-7 93142-34-8 96535-48-7 97000-94-7 97790-70-0 97790-71-1
98144-07-1 **98177-71-0** 98177-79-8 98179-12-5 98179-13-6
98179-14-7 98221-76-2 98249-90-2 98346-66-8 98346-67-9 98565-05-0
98579-00-1 98924-97-1 98924-98-2 98925-07-6 99672-42-1 99710-31-3
99801-54-4 101014-71-5 101811-55-6 102031-04-9 102031-05-0 103005-48-7
105015-83-6 106216-76-6 107927-09-3
IT **98177-71-0**
RN 98177-71-0 HCAOLD
CN Adenosine, 3'-amino-N-benzyl-3'-deoxy- (6CI, 7CI) (CA INDEX NAME)

Absolute stereochemistry.



L16 ANSWER 2 OF 5 HCAOLD COPYRIGHT 2002 ACS
AN CA57:10372h CAOLD
TI nucleotide and polynucleotide synthesis in Trypanosoma cruzi - (VII) precursors of the pyrimidine nucleotides
AU Rey, Louis; Fernandes, J. F.
IT 6088-33-1 71528-47-7 **98177-71-0** 98346-67-9 98579-00-1
IT **98177-71-0**
RN 98177-71-0 HCAOLD
CN Adenosine, 3'-amino-N-benzyl-3'-deoxy- (6CI, 7CI) (CA INDEX NAME)

Absolute stereochemistry.



L16 ANSWER 3 OF 5 HCAOLD COPYRIGHT 2002 ACS
AN CA53:8175d CAOLD
TI aminodeoxyglycosidopurines
AU Baker, Bernard Randall; Joseph, J. P.; Schaub, R. E.
PA American Cyanamid Co.
DT Patent

PATENT NO.	KIND	DATE
PI US 2852505		1958

IT 72-94-6 3068-34-6 6044-48-0 6088-33-1 6997-08-6 14365-44-7
21299-78-5 22738-78-9 34522-42-4 71528-47-7 96535-48-7 97790-70-0
97790-71-1 98144-07-1 **98177-71-0** 98179-13-6 98346-66-8
98565-05-0 98579-00-1 98925-07-6 99672-42-1 99710-31-3 99801-54-4
100245-75-8 101811-55-6 102031-04-9 102031-05-0 108564-69-8 108761-17-7
109038-94-0 109366-69-0 109366-70-3 109367-58-0 109514-96-7 109588-18-3
109588-19-4 110115-47-4 110441-03-7 112023-24-2 113134-74-0 115101-58-1
115120-96-2 116606-84-9 117099-14-6 117884-13-6 119149-43-8 119149-44-9
119249-28-4 119597-43-2 119622-10-5 119622-11-6 119659-44-8 119927-07-0
120945-44-0 121316-54-9 121970-12-5 121970-21-6 121990-69-0 122147-87-9
122148-06-5 122148-09-8 122240-49-7 122595-60-2 122626-07-7 123838-76-6
124103-68-0 124103-84-0 124107-95-5 125614-54-2 125614-55-3 125710-80-7
132129-29-4 133498-35-8 133498-36-9

IT **98177-71-0**
RN 98177-71-0 HCAOLD
CN Adenosine, 3'-amino-N-benzyl-3'-deoxy- (6CI, 7CI) (CA INDEX NAME)

Absolute stereochemistry.



L16 ANSWER 4 OF 5 HCAOLD COPYRIGHT 2002 ACS
AN CA53:8174e CAOLD
TI aminodeoxyglycosidopurines
PA American Cyanamid Co.
DT Patent
IT 72-94-6 6044-48-0 6088-33-1 34522-42-4 71528-47-7 96535-48-7
97790-70-0 97790-71-1 98144-07-1 **98177-71-0** 98179-13-6
98346-66-8 98565-05-0 98579-00-1 98925-07-6 99710-31-3 99801-54-4
101811-55-6 102031-04-9 102031-05-0 109367-58-0 110441-03-7 112023-25-3
117884-13-6 119597-43-2 119622-10-5 119622-11-6 120945-44-0 121970-21-6
124107-95-5
IT **98177-71-0**
RN 98177-71-0 HCAOLD
CN Adenosine, 3'-amino-N-benzyl-3'-deoxy- (6CI, 7CI) (CA INDEX NAME)

Absolute stereochemistry.



L16 ANSWER 5 OF 5 HCAOLD COPYRIGHT 2002 ACS
AN CA51:1206e CAOLD
TI reactions in sunlight with alc. NH3 - (IV) action of 4,5-diphenyl-3-benzoylisoxazole, benzoin, benzil, deoxybenzoin, and benzaldehyde, (V) reaction with N-substituted pyrroles and .omega.-desylacetophenone, (VI) reaction with indolic compds.
AU Capuano, Salvatore; Giammanco, L.
IT 86-96-4 92-29-5 493-77-6 948-65-2 1022-45-3 1666-86-0
1917-44-8 4441-01-4 6707-63-7 13901-77-4 15345-47-8 20198-19-0
96535-48-7 97790-71-1 98144-07-1 **98177-71-0** 98179-12-5
98179-13-6 98221-76-2 98346-67-9 98565-05-0 98925-07-6 103166-35-4
IT **98177-71-0**

RN 98177-71-0 HCAOLD
CN Adenosine, 3'-amino-N-benzyl-3'-deoxy- (6CI, 7CI) (CA INDEX NAME)

Absolute stereochemistry.



=> fil hcaplus
FILE 'HCAPLUS' ENTERED AT 15:39:47 ON 07 AUG 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 7 Aug 2002 VOL 137 ISS 6
FILE LAST UPDATED: 6 Aug 2002 (20020806/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

CAS roles have been modified effective December 16, 2001. Please check your SDI profiles to see if they need to be revised. For information on CAS roles, enter HELP ROLES at an arrow prompt or use the CAS Roles thesaurus (/RL field) in this file.

=> d all tot l24

L24 ANSWER 1 OF 5 HCAPLUS COPYRIGHT 2002 ACS
AN 1963:428787 HCAPLUS
DN 59:28787
OREF 59:**5251g-h,5252a**
TI Synthesis and reactions of 3'-amino-3'-deoxyribosides of 6-chloropurine
AU Goldma, L.; Marsic, J. W.
CS Am. Cyanamid Co., Pearl River, NY
SO J. Med. Chem. (1963), 6(4), 413-23
DT Journal
LA Unavailable
CC 43 (Carbohydrates)
GI For diagram(s), see printed CA Issue.
AB Blocked 3'-amino-6-chloronucleosides [I (R = phthalimido,.beta.-anomer)

(II) and I (R = AcNH) (III)] were synthesized and found to be excellent intermediates for the prepn. of analogs of the puromycin aminonucleoside (IV). Chloride was displaced from II and III by primary and secondary amines in methanol with simultaneous removal of the O-benzoyl groups. Primary amines removed the N-phthaloyl group of II, whereas secondary amines opened the N-phthaloyl group to produce N,N,N'-trisubstituted phthalamides. Primary amines cleaved the latter phthalamides to produce unblocked 3'-amino-3'-deoxynucleosides. Diisopropylamine failed to displace chloride from II and failed to open the phthalimide function. Several analogs of the puromycin aminonucleoside were found to possess enhanced trypanocidal activity. The application of proton magnetic resonance spectral measurements to detn. of anomeric configuration in ribofuranoses is discussed.

L24 ANSWER 2 OF 5 HCAPLUS COPYRIGHT 2002 ACS
AN 1962:451930 HCAPLUS
DN 57:51930
OREF 57:**10372h-i**
TI Nucleotide and polynucleotide synthesis in Trypanosoma cruzi. VII. Precursors of the pyrimidine nucleotides
AU Roy, L.; Fernandes, J. F.
CS Univ. Sao Paulo, Brazil
SO Exptl. Parasitol. (1962), 12, 55-60
DT Journal
LA Unavailable
CC 68 (Nonmammalian Biochemistry)
AB The rate of incorporation of uracil-C14 (I) and orotic acid-C14 (II) into the acid-sol. nucleotides (III) and mixed nucleic acid pyrimidines was detd. The rate of incorporation of I was much greater than that of II, principally in the III fraction. Total utilization of I is 5-7% of the added I, compared to 0.25% with II. 6-Propyl-2-thiouracil inhibits slightly the conversion of uridylic acid (IV) into cytidylic acid (V), but has very little effect on the incorporation of I into IV. 5-Fluorouracil strongly inhibits incorporation of I into IV but does not affect the conversion of IV into V.

L24 ANSWER 3 OF 5 HCAPLUS COPYRIGHT 2002 ACS
AN 1959:45326 HCAPLUS
DN 53:45326
OREF 53:**8175d-i,8176a-i,8177a-g**
TI Aminodeoxyglycosidopurines
IN Baker, Bernard R.; Joseph, Joseph P.; Schaub, Robert E.
PA American Cyanamid Co.
DT Patent
LA Unavailable
CC 10G (Organic Chemistry: Heterocyclic Compounds)
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2852505		19580916	US	

AB Potential chemotherapeutic aminonucleosides, aminodeoxyglycosidopurines (I), have been prepd. I are related to the glycosidopurines (nucleosides) but are active in the treatment of Trypanosomiasis in cattle, and may be referred to as aminonucleosides. A new and novel method of prepn. of I is to treat a mixt. contg. a heavy metal salt of a purine and an acylated amino sugar with TiCl4 in an inert hydrocarbon or halogenated hydrocarbon solvent at 50-90.degree.. Thus, 2-methylthio-6-dimethylamino-9-(2,5-di-O-benzoyl-3-acetamido-3-deoxy-.beta.-D-ribofuranosyl)purine (II) was prepd. as follows. To 5.1 g. Me 2,5-di-O-benzoyl-3-acetamido-3-deoxy-.beta.-D-ribofuranoside in 100 ml. of MeOH was added 1.8 ml. N NaOMe in MeOH, the soln. refluxed 30 min., and evapd. to dryness in vacuo to leave Me 3-acetamido-3-deoxy-.beta.-D-ribofuranoside as a glass. This was dissolved in 50 ml. dry pyridine and treated with 5.1 ml. BzCl at

5-7.degree.. After 68 hrs. in a closed container at 3.degree., the mixt. was dild. with 200 ml. H2O and extd. with 3 50-ml. portions CHCl3, the exts. washed with aq. NaHCO3, dried, treated with C, evapd. to dryness in vacuo, and the residue pptd. from 14 ml. benzene by addn. of heptane to turbidity to give 64% Me 2,5-di-O-benzoyl-3-acetamido-3-deoxy-.beta.-D-ribofuranoside (III), m. 139-41.degree.. To 5 g. III was added 15 ml. concd. aq. HCl, the mixt. stirred at 50.degree. 25 min. and then dild. with 175 ml. of ice water, extd. with 175 ml. CHCl3 in 3 portions, the ext. treated as before, and the residue crystd. from 10 ml. EtOAc by addn. of heptane to turbidity to give 52% 2,5-di-O-benzoyl-3-acetamido-3-deoxy-D-ribose (IV), m. 153-4.degree., [.alpha.]D 108.degree. (pyridine). IV (2.5 g.) in 5 ml. pyridine and 5 ml. Ac2O was heated on a steam bath 1 hr., dild. with 25 ml. ice water, extd. with 55 ml. CHCl3, and the ext. treated as before to leave 98% gummy solid, m. 127-31.degree., a mixt. of .alpha.- and .beta.-1-(O-acetyl)-2,5-di-O-benzoyl-3-acetamido-3-deoxy-D-ribofuranoside (V). Recrystn. from 16 ml. 1:1 EtOAc-heptane gave one of the isomers of V, m. 152-4.degree., [.alpha.]24D 63.degree. (pyridine). The other isomer was a noncrystallizable gum, [.alpha.]24D 84.degree. (2%, pyridine). To 990 mg. .alpha.,.beta.-mixt. of V in 8.5 ml. ethylene dichloride was added 0.30 ml. TiCl4 in 4.4 ml. of the same solvent, after refluxing 1 hr. the soln. added to a stirred mixt. of 1.25 g. 2-methylthio-6-(dimethylamino)purine mercuric chloride reaction product, 1.35 g. of diatomaceous earth, and 90 ml. ethylene chloride which had previously been dried by distn. of 20 ml. solvent, the mixt. stirred and refluxed 18 hrs., treated with 45 ml. water, stirred without further heating 15 min., filtered, the solids washed with hot CHCl3, the org. layer and the washings evapd. to dryness in vacuo, the glass dissolved in 25 ml. HCl3, washed with 25 ml. 30% aq. KI then water, the org. layer dried, treated with activated C, and evapd. to dryness in vacuo to leave 100% glass, .lambda. 282.5 m.mu. (.epsilon. 17,000) (Methyl Cellosolve), corresponding to 94% pure 2 - methylthio-6-dimethylamino-9-(2,5-di-O-benzoyl-3-acetamido-3-deoxy-.beta.-D-ribofuranosyl)purine. (VI). VI (1.28 g.) in 75 ml. Methyl Cellosolve was stirred with 2 teaspoons of desulfurizing Raney Ni on the steam bath 40 min., the soln. filtered hot, the catalyst washed with addnl. solvent, and the soln. evapd. to dryness in vacuo left 60% 6-dimethylamino-9-(2,5-di-O-benzoyl-3-acetamido-3-deoxy-.beta.-D-ribofuranosyl)purine (VII), glass, .lambda. 275 m.mu. (.epsilon. 16,900) (Methyl Cellosolve), corresponding to 90% purity. VII (690 mg.) in 15 ml. MeOH and 0.14 ml. N NaOMe in MeOH was refluxed 30 min., evapd. to dryness in vacuo, and the residue crystd. from 3 ml. alc. to yield 30% 6-dimethylamino-9-(3-acetamido-3-deoxy-.beta.-D-ribofuranosyl)purine (VIII), m. 187-8.degree., [.alpha.]D -9.9.degree. (3%, pyridine). VIII (100 mg.) in 5 ml. 0.5N Ba(OH)2 was heated on a steam bath 1 hr., the Ba(OH)2 pptd. with excess CO2, the soln. filtered, the filtrate evapd. to dryness in vacuo, the residue dissolved in 3 ml. water, filtered, the soln. evapd., and the residue triturated with 3 ml. EtOAc to give 80% 6-dimethylamino-9-(3-amino-3-deoxy-.beta.-D-ribofuranosyl)purine, m. 215-16.degree. (abs. EtOH), [.alpha.]25D -24.6.degree. (H2O), .lambda. 276 m.mu. (.epsilon. 18,900) (pH 7). The following were prepd. by similar techniques: 2-methylthio-6-dimethylamino-9-(2-acetamido-2-deoxy-3,4,6-tri-O-acetyl-.beta.-D-glucopyranosyl)purine, m. 238-40.degree., [.alpha.]24D 8.5.degree. (1.8%, CHCl3); 1-chloro-2-acetamido-2-deoxy-3,4,6-tri-O-acetyl-.alpha.-D-glucopyranoside, m. 125-6.degree. (decompn.); 2-methylthio-6-dimethylamino-9-(2-acetamido-2-deoxy-.beta.-D-glucopyranosyl)purine, m. 245-7.degree. (decompn.); 6-dimethylamino-9-(2-acetamido-2-deoxy-3,4,6-tri-O-acetyl-.beta.-D-glucopyranosyl)purine; 6-dimethylamino-9-(2-acetamido-2-deoxy-.beta.-D-glucopyranosyl)purine, m. about 170.degree.; 2,5-di-O-benzoyl-3-acetamido-3-deoxy-D-arabinose, m. 152-3.degree., [.alpha.]D -25.6.degree. (CHCl3); 2-methylthio-6-dimethylamino-9-(2,5-di-O-benzoyl-3-acetamido-3-deoxy-.alpha.-D-arabinofuranosyl)purine, glass; 6-dimethylamino-9-(2,5-di-O-benzoyl-3-acetamido-3-deoxy-.alpha.-D-arabinofuranosyl)purine, glass; 6-dimethylamino-9-(3-acetamido-3-deoxy-.alpha.-D-arabinofuranosyl)purine,

m. 189-91.degree. [.alpha.]D 102.degree. (water); 6-dimethylamino-9-(2,5-di-O-acetyl-3-acetamido-3-deoxy-.alpha.-D-ribofuranosyl)purine, glass; 6-dimethylamino-9-(3-acetamido-3-deoxy-.alpha.-D-ribofuranosyl)purine, m. 239-40.degree., [.alpha.]25D 115.degree. (H2O); 6-dimethylamino-9-(3-amino-3-deoxy-.alpha.-D-ribofuranosyl)purine, m. 235.degree. (decompn.); 6-amino-9-(3-acetamido-3-deoxy-.alpha.-D-ribofuranosyl)purine, m. 279.degree. (decompn.), [.alpha.]24D 60.degree. (0.1N HCl); 6-amino-9-(3-acetamido-3-deoxy-.beta.-D-ribofuranosyl)purine, m. 234-44.degree. (decompn.), [.alpha.]25D 11.6.degree. (0.1N HCl); 6-dimethylamino-9-(3-phthalimido-3-deoxy-.beta.-D-ribofuranosyl)purine, m. 274-5.degree. (decompn.); 6-chloro-9-(2,5-di-O-benzoyl-3-phthalimido-3-deoxy-.beta.-D-ribofuranosyl)purine (contg. 0.5 mole of EtOAc), sinters to a glass at 76-7.degree., m. 100-5.degree. to a glass, [.alpha.]24D -60.9.degree. (CHCl3); 6-chloro-9-(2,5-di-O-benzoyl-3-acetamido-3-deoxy-D-ribofuranosyl)purine, light tan glass, [.alpha.]24.5D 39.2.degree. (EtOH); 6-dimethylamino-9-(3-acetamido-3-deoxy-.beta.-D-ribofuranosyl)purine, m. 186-9.degree., [.alpha.]25D -8.1.degree. (pyridine); 6-diethylamino-9-(3-acetamido-3-deoxy-.beta.-D-ribofuranosyl)purine, m. 214.5-15.0.degree., [.alpha.]24.5D -26.0.degree. (EtOH); 6-diethylamino-9-(3-amino-3-deoxy-.beta.-D-ribofuranosyl)purine, m. 181-3.degree., [.alpha.]24.5D -45.8.degree. (EtOH); 6-methylamino-9-(3-amino-3-deoxy-.beta.-D-ribofuranosyl)purine, m. 228.5-30.5.degree., [.alpha.]24D -29.6.degree. (water); 6-isobutylamino-9-(3-amino-3-deoxy-.beta.-D-ribofuranosyl)purine, m. 171.5-2.5.degree., [.alpha.]24D -25.3.degree. (water); 6-dimethylamino-9-(3-amino-3-deoxy-.beta.-D-ribofuranosyl)purine, m. 214-16.degree.; 6-(1-piperidyl)-9-(3-[2-(1-piperidylcarbonyl)benzamido]-3-deoxy-.beta.-D-ribofuranosyl)purine, tan glass; 6-(1-piperidyl)-9-(3-amino-3-deoxy-.beta.-D-ribofuranosyl)purine (hemihydrate), m. 189.5-90.0.degree., [.alpha.]24D -44.0.degree. (EtOH); 6-dipropylamino-9-(3-amino-3-deoxy-.beta.-D-ribofuranosyl)purine, plates m. 168.5-9.5.degree., [.alpha.]24D -45.0.degree. (MeOH); 2,6-dichloro-9-(2,5-di-O-benzoyl-3-phthalimido-3-deoxy-D-ribofuranosyl)purine, sintered to a glass at 58-60.degree. and m. 95-105.degree. to a glass, [.alpha.]28D -57.0.degree. (CHCl3); 6-methylamino-9-(3-acetamido-3-deoxy-.alpha.(and .beta.)-D-ribofuranosyl)purine, .alpha.-form, needles, m. 257-8.degree. (decompn.), [.alpha.]28D 114.0.degree. (water), .beta.-form (contg. 0.25 mole water), m. 229-30.degree. (decompn.), [.alpha.]28D -2.0.degree. (water); 6-methylamino-9-(3-amino-3-deoxy-.beta.-D-ribofuranosyl)purine, m. 230-1.degree., [.alpha.]25D -26.9.degree. (water); 6-diethylamino-9-(3-amino-3-deoxy-.beta.-D-ribofuranosyl)purine, m. 181.5-2.5.degree., [.alpha.]25D -44.0.degree. (EtOH); 6-dibutylamino-9-(3-amino-3-deoxy-.beta.-D-ribofuranosyl)purine, m. 189.5-90.5.degree., [.alpha.]26D -38.8.degree. (MeOH); 6-furfurylamino-9-(3-amino-3-deoxy-.beta.-D-ribofuranosyl)purine, m. 157.5-8.5.degree., [.alpha.]26D -43.5.degree. (water); 6-benzylamino-9-(3-amino-3-deoxy-.beta.-D-ribofuranosyl)purine, m. 174.5-5.5.degree., [.alpha.]25D -41.8.degree. (MeOH); 6-methoxy-9-(3-phthalimido-3-deoxy-.beta.-D-ribofuranosyl)purine, m. 243-4.degree. (decompn.), [.alpha.]26D -113.0.degree. (MeOH); 6-diamylamino-9-(3-amino-3-deoxy-.beta.-D-ribofuranosyl)purine, m. 172-3.2.degree., [.alpha.]26D -43.7.degree. (EtOH); 6-diheptylamino-9-(3-amino-3-deoxy-.beta.-D-ribofuranosyl)purine, m. 137-8.degree., [.alpha.]25d -36.9.degree. (EtOH); 6-mercapto-9-(2,5-di-O-benzoyl-3-phthalimido-3-deoxy-.beta.-D-ribofuranosyl)purine, m. 233-8.degree., [.alpha.]26D -105.0.degree. (pyridine); 2-chloro-6-dipropylamino-9-(3-amino-3-deoxy-D-ribofuranosyl)purine, plates, m. 164.5-5.5.degree. [.alpha.]25D -23.6.degree. (EtOH); 6-methylthio-9-(2,5-di-O-benzoyl-3-phthalimido-3-deoxy-D-ribofuranosyl)purine, m. 157-9.degree. and 195.5-196.5.degree., [.alpha.]25D -88.4.degree. (CHCl3); 9-(2,5-di-O-benzoyl-3-phthalimido-3-deoxy-D-ribofuranosyl)purine (hydrate), m. 117.5-22.degree., [.alpha.]25D -61.7.degree. (CHCl3); 6-decylamino-9-(3-amino-3-deoxy-.beta.-D-ribofuranosyl)purine, m. 138-9.degree., [.alpha.]25D -40.0.degree. (EtOH); 6-diallylamino-9-(3-

amino-3-deoxy-.beta.-D-ribofuranosyl)purine, m. 161-3.5.degree., [.alpha.]25D -43.1.degree. (MeOH); 6-(4-morpholinyl)-9-(3-[.omicron.-(4-morpholinylcarbonyl)benzamido]-3-deoxy-.beta.-D-ribofuranosyl)purine, tan glass, [.alpha.]24D -16.6.degree. (EtOH); 6-butylamino-9-(3-amino-3-deoxy-.beta.-D-ribofuranosyl)purine, (contg. 0.25 mole water), m. 171-2.degree., [.alpha.]25D -43.7.degree. (EtOH); 6-cyclohexylamino-9-(3-amino-3-deoxy-.beta.-D-ribofuranosyl)purine, glass, [.alpha.]25D -42.5.degree. (EtOH); 6-chloro-9-(2,3-di-O-benzoyl-5-phthalimido-5-deoxy-.beta.-D-ribofuranosyl)purine, fluffed glass; 9-(2,3-di-O-benzoyl-5-phthalimido-5-deoxy-.beta.-D-ribofuranosyl)purine, m. 153-5.degree.; 9-(5-amino-5-deoxy-.beta.-D-ribofuranosyl)purine, m. 148-55.degree. (decompn.); 6-dimethylamino-9-(2,3-di-O-benzoyl-5-phthalimido-5-deoxy-.beta.-D-ribofuranosyl)purine, m. 230-2.degree.; 6-dimethylamino-9-(5-amino-5-deoxy-.beta.-D-ribofuranosyl)purine, m. 132-3.degree.; 2-methylthio-6-dimethylamino-9-(2-acetamido-2-deoxy-4,6-O-benzylidene-.beta.-D-glucopyranosyl)purine, tan crystals, m. 254-5.degree. (decompn.); 2-methylthio-6-dimethylamino-9-[2-acetamido-2-deoxy-3-mesyl-4,6-(O-benzylidene)-.beta.-D-glucopyranosyl] purine, gray crystals, m. 201-2.degree.; 2-methylthio-6-dimethylamino-9-[2-acetamido-2-deoxy-4,6-(O-benzylidene)-.beta.-D-allopyranosyl]purine, m. 229-31.degree. (decompn.); 2-methylthio-6-dimethylamino-9-[2-acetamido-2-deoxy-3-(O-acetyl)-4,6-(O-benzylidene)-.beta.-D-allopyranosyl] purine, m. 204-5.degree. (decompn.); 2-methylthio-6-dimethylamino-9-(2-acetamido-2-deoxy-3,4,6-tri-O-acetyl-.beta.-D-allopyranosyl)purine, m. 197-8.degree.; 6-dimethylamino-9-(2-acetamido-2-deoxy-.beta.-D-allopyranosyl)purine, m. 250-3.degree. (decompn.); 6-dimethylamino-9-(2-amino-2-deoxy-.beta.-D-allopyranosyl)purine, m. 110-12.degree.; Et 2-acetamido-2-deoxy-3,5,6-tri-O-benzoyl-.alpha.-D-glucothiofuranoside, m. 113-14.degree.; 3-acetamido-3-deoxy-D-altrose diethylmercaptal, m. 133-5.degree.; 3-acetamido-3-deoxy-6-(O-trityl)-D-altrose diethylmercaptal, m. 91-2.degree.; 2-acetamido-2-deoxy-4-(O-formyl)-5-(O-trityl)-D-ribose, m. 140-3.degree., 6-dimethylamino-9-(3-amino-3-deoxy-.beta.-D-allopyranosyl)purine hemihydrate, m. 178-80.degree., [.alpha.]25D -17.9.degree. (water); 2-methylthio-6-dimethylamino-9-(3-acetamido-3-deoxy-.beta.-D-arabinofuranosyl)purine, m. 193-5.degree., [.alpha.]25D 13.degree. (2%, pyridine); 9-(3-phthalimido-3-deoxy-.beta.-D-ribofuranosyl)adenine, buff-colored crystals, m. 228-9.degree., [.alpha.]24D -175.degree. (0.6%, EtOH); and other similar compds. which were gums, syrups, and glasses and were not described further.

L24 ANSWER 4 OF 5 HCAPLUS COPYRIGHT 2002 ACS
AN 1959:45325 HCAPLUS
DN 53:45325
OREF 53:**8174b-i,8175a-d**
TI Aminodeoxyglycosidopurines
IN Goldman, Leon; Marsico, Joseph W.
PA American Cyanamid Co.
DT Patent
LA Unavailable
CC 10G (Organic Chemistry: Heterocyclic Compounds)
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2852506		19580916	US	

AB The condensation of a blocked deriv. of a glycoside with a suitably substituted purine results in aminodeoxyglycosidopurines (I). Thus, 6-chloro(chloromercuri)purine (II) and bis(6-chloropurinyl)mercury (III) were prepd. by adding 3.091 g. 6-chloropurine to 50 ml. 0.4 Naq. NaOH at 75.degree. followed by immediate addn. of a hot soln. of 5.430 g. $HgCl_2$ in 15 ml. EtOH with stirring. The crystals which formed were cooled, filtered, water-washed, and dried at 100.degree.. The yield of light tan crystals, analyzing for 15% II and 85% III was 96%. To a stirred refluxing suspension of a mixt. (6.84 g.) of 82.5% III and 17.5% II in 350

ml. of anhyd. xylene was added a hot soln. of 11.86 g. 2,5-di-O-benzoyl-3-phthalimido-3-deoxy-.beta.-D-ribofuranosyl chloride in 125 ml. anhyd. xylene, the suspension refluxed and stirred 5 hrs., filtered while hot, the filter cake washed with hot CHCl3, the combined filtrate and wash washed with 30% aq. KI and then water, the soln. dried, and evapd. in vacuo to give 13.36 g. 6-chloro-9-(2,5-di-O-benzoyl-3-phthalimido-3-deoxy-.beta.- D-ribofuranosyl) purine (IV), recrystd. from EtOAc-hexane to 7.18 g. IV contg. 0.5 mole EtOAc, sintered at 76-7.degree. to an opaque glass and m. 100-105.degree., [.alpha.]24D -60.9.degree. (CHCl3), .lambda. 263 m.mu. (.epsilon. 12,100) (0.1N HCl), .lambda. 263 m.mu. (.epsilon. 10,700) (EtOH and 0.1N NaOH). IV (0.536 g.), 1 ml. Me2NH, and 10 ml. anhyd. MeOH was heated in a sealed tube 2 hrs. on a steam bath, the red-brown soln. evapd. in vacuo, the gummy residue dissolved in aq. EtOH, evapd. to dryness in vacuo, the residue dissolved in 40 ml. 50% MeOH, 38.4 ml. of the soln. stirred with Amberlite RA-400 (OH) resin, the suspension filtered, and the filtrate evapd. in vacuo to yield 96% 6-dimethylamino-9-(3-acetamido-3-(deoxy-D-ribofuranosyl)purine (V), m. 186-9.degree. (alc.), [.alpha.]25D -8.1.degree. (pyridine), .lambda. 267 m.mu. (.epsilon. 17,700) (0.1N HCl), .lambda. 275 m.mu. (.epsilon. 17,500) (EtOH), .lambda. 275 m.mu. (.epsilon. 17,800) (0.1N NaOH). Similarly the following were prepd.: 6-chloro-9-(2,5-di-O-benzoyl-3-acetamido-3-deoxy-D-ribofuranosyl)purine, light tan glass, [.alpha.]24.5D 39.2.degree. (EtOH); 6-dimethylamino-9-(3-acetamido-3-deoxy-.beta.-D-ribofuranosyl)purine, m. 186-9.degree., [.alpha.]25D -8.1.degree. (pyridine); 6-diethylamino-9-(3-acetamido-3-deoxy-.beta.-D-ribofuranosyl)-purine, m. 214.5-15.0.degree., [.alpha.]24.5D -26.0.degree. (EtOH); 6-diethylamino-9-(3-amino-3-deoxy-.beta.-D-ribofuranosyl)purine, m. 181-3.degree. [.alpha.]24.5D -45.8.degree. (EtOH); 6-methylamino-9-(3-amino-3-deoxy-.beta.-D-ribofuranosyl)purine, m. 228.5-30.5.degree., [.alpha.]24D -29.6.degree. (water); 6-isobutylamino-9-(3-amino-3-deoxy-.beta.-D-ribofuranosyl)purine, m. 171.5-2.5.degree., [.alpha.]24D -25.3.degree. (water); 6-dimethylamino-9-(3-amino-3-deoxy-.beta.-D-ribofuranosyl)purine, m. 214-16.degree. 6-(1-piperidyl)-9-(3-[o-(1-piperidylcarbonyl)benzamido]-3-deoxy-.beta.-D-ribofuranosyl)purine, tan glass; 6-(1-piperidyl)-9-(3-amino-3-deoxy-.beta.-D-ribofuranosyl)purine hemihydrate, m. 189.5-90.0.degree., [.alpha.]24D -44.0.degree. (EtOH); 6-dipropylamino-9-(3-amino-3-deoxy-.beta.-D-ribofuranosyl)purine, plates, m. 168.5-9.5.degree., [.alpha.]24D -45.0.degree. (MeOH); 2,6-dichloro-9-(2,5-di-O-benzoyl-3-phthalimido-3-deoxy-D-ribofuranosyl)purine, sintered at 58-60.degree. and m. 95-105.degree., [.alpha.]28D -57.0.degree. (CHCl3); 6-methylamino-9-(acetamido-3-deoxy-D-ribofuranosyl)purine .alpha.-form (contg. 0.25 mole water), m. 257-8.degree., [.alpha.]28D 114.degree. (water), .beta.-form (contg. 0.25 mole water), m. 229-30.degree. (decompn.), [.alpha.]28D -2.0.degree. (water); 6-methylamino-9-(3-amino-3-deoxy-.beta.-D-ribofuranosyl)purine, m. 230-1.degree., [.alpha.]25D -26.9.degree. (water); 6-diethylamino-9-(3-amino-3-deoxy-.beta.-D-ribofuranosyl)purine, m. 181.5-2.5.degree., [.alpha.]25D -44.0.degree. (EtOH); 6-dibutylamino-9-(3-amino-3-deoxy-.beta.-D-ribofuranosyl)purine, m. 189.5-90.5.degree., [.alpha.]26D -38.8.degree. (MeOH); 6-furfuryl-9-(3-amino-3-deoxy-.beta.-D-ribofuranosyl)purine, m. 157.5-8.5.degree., [.alpha.]26D -43.5.degree. (water); 6-benzylamino-9-(3-amino-3-deoxy-.beta.-D-ribofuranosyl)purine, m. 174.5-5.5.degree., [.alpha.]25D -41.8.degree. (MeOH); 6-methoxy-9-(3-phthalimido-3-deoxy-.beta.-D-ribofuranosyl)purine, m. 243-4.degree. (decompn.), [.alpha.]26D -113.0.degree. (MeOH); 6-diamylamino-9-(3-amino-3-deoxy-.beta.-D-ribofuranosyl)purine, m. 172-3.2.degree., [.alpha.]26D -43.7.degree. (EtOH); 6-diheptylamino-9-(3-amino-3-deoxy-.beta.-D-ribofuranosyl)purine, m. 137-8.degree., [.alpha.]25D -36.9.degree. (EtOH); 6-mercapto-9-(2,5-di-O-benzoyl-3-phthalimido-3-deoxy-.beta.-D-ribofuranosyl)purine, m. 233-8.degree., [.alpha.]26D -105.degree. (pyridine); 2-chloro-6-propylamino-9-(3-amino-3-deoxy-D-ribofuranosyl)purine, plates, m. 164.5-5.5.degree., [.alpha.]25D -23.6.degree. (EtOH); 6-methylthio-9-(2,5-di-O-benzoyl-3-phthalimido-3-

deoxy-D-ribofuranosyl)purine, partially m. 157-9.degree. and m. 195.5-6.5.degree., [.alpha.]25D -88.4.degree. (CHCl3); 9-(2,5-di-O-benzoyl-3-phthalimido-3-deoxy-D-ribofuranosyl)purine (hydrate), m. 117.5-22.degree., [.alpha.]25D -61.7.degree. (CHCl3); 6-decylamino-9-(3-amino-3-deoxy-.beta.-D-ribofuranosyl)purine, m. 138-9.degree., [.alpha.]25D -40.0.degree. (EtOH); 6-diallylamino-9-(3-amino-3-deoxy-.beta.-D-ribofuranosyl)purine, m. 161-3.5.degree., [.alpha.]25D -43.1.degree. (MeOH); 6-(4-morpholinyl)-9-(3-[O-(4-morpholinylcarbonyl)benzamido]-3-deoxy-.beta.-D-ribofuranosyl)purine, tan glass, [.alpha.]24D -16.6.degree. (EtOH); 6-butylamino-9-(3-amino-3-deoxy-.beta.-D-ribofuranosyl)purine (contg. 0.25 mole water), m. 171-2.degree., [.alpha.]25D -43.7.degree. (EtOH); 6-cyclohexylamino-9-(3-amino-3-deoxy-.beta.-D-ribofuranosyl)purine, glass, [.alpha.]25D -42.5.degree. (EtOH); 9-(2,3-di-O-benzoyl-5-phthalimido-5-deoxy-.beta.-D-ribofuranosyl)purine, m. 153-5.degree.; 9-(5-amino-5-deoxy-.beta.-D-ribofuranosyl)purine, decomp. 148-55.degree.; Et 2-acetamido-2-deoxy-3,5,6-tri-O-benzoyl-.alpha.-D-glucothiofuranoside, m. 113-14.degree.; and several other compds. without phys. props.

L24 ANSWER 5 OF 5 HCAPLUS COPYRIGHT 2002 ACS
AN 1957:5534 HCAPLUS
DN 51:5534
OREF 51:**1206e-i,1207a-b**
TI Reactions in sunlight with alcoholic ammonia. IV. The action on 4,5-diphenyl-3-benzoylisoxazole, benzoin, benzil, deoxybenzoin, and benzaldehyde
AU Capuano, Salvatore; Giammanco, Lorenzo
CS Univ. Palermo, Italy
SO Gazz. chim. ital. (1956), 86, 109-18
DT Journal
LA Unavailable
CC 10 (Organic Chemistry)
GI For diagram(s), see printed CA Issue.
AB cf. C.A. 47, 8061f; 50, 7807f. Although the mechanism of the action of alc. NH3 on PhC:CPh. N: CPh.C: NOH (I) in sunlight was not explained in the previous work, it seemed possible that the reaction started by hydrolysis and loss of NH3 to HOCPh: CPhCBz:NOH, which gave BzPhCHCBz:NOH (II), and that the subsequent reactions depend on the formation of II. This induced C. and G. to test the same reaction with 4,5-diphenyl-3-benzoylisoxazole (III) because III can be regarded as the anhydride of I. III (40 g.) added to 1000 cc. 95% EtOH satd. with dry NH3, the mixt. allowed to stand closed in sunlight for 50 days, in which time the initially insol. portion dissolves, the soln. becomes wine-red, and (NH4)2CO3 or H2NCO2NH4 is deposited, the soln. concd. in vacuo, the brown-red oil allowed to crystallize, the mass extd. with hot H2O, EtOH added to the brown oil, the solidified yellow mass washed with EtOH, and purified by dioxane, gives 2,4-diphenyl-6-hydroxy-s-triazine (IV), m. 293.degree.. In addn. to the method of Pinner [Ber. 23, 2920 (1893)], IV can be synthesized by heating (H2N)2CO and HN:CPhNH2.HCl (2 moles) until fused, keeping fused 5 min. (NH3 and NH4Cl are evolved), cooling, adding H2O, boiling the mixt., filtering hot, washing the residue exhaustively with hot H2O, and crystg. from EtOH. The mother liquor of the ext. of the mass obtained by concn. of the original reaction liquid in the prepn. of IV, evapd., the oil allowed to crystallize, and purified by PhMe, give BzNH2. The mother liquor contains BzOH. BzCHPhOH (40 g.) added as was III to alc. NH3, and the mixt. exposed to sunlight 4 months, gives a yellow soln. contg. an insol. cryst. product; the latter, washed with EtOH and purified by AcOH, gives 2,4,6-triphenyl-s-triazine (V), m. 235.degree.. The yellow mother liquor, evapd. in vacuo, and the oil purified, yields BzNH2. Bz2 (20 g.) and 1000 cc. alc. NH3 give an orange-yellow soln., which, exposed 3 months to sunlight, and the ppt. purified by EtOH, give V. The mother liquor contains BzNH2 and BzOH. PhCH2Bz (20 g.) and 1000 cc. alc. NH3 give a yellow soln., which, exposed

6 months to sunlight, yields V, BzNH2, and BzONH4. Bz2 or BzCH-PhOH or PhCH2Bz in alc. NH3, exposed 1 month to sunlight, the product concd. in vacuo, and the residue steam distd., gives BzH. BzH (20 g.) and 400 cc. alc. NH3, exposed (while closed) to sunlight for 80 days, give a yellow soln. and cryst. deposit; the mixt. (odor of NH3 and BzH) filtered, and the residue purified by hot EtOH, give PhCH(N:CHPh)2 (VI), m. 110.degree.. Treated again with alc. NH3, VI dissolves slowly and by exposure to sunlight for 3 months, V separates. Possible mechanisms of the various reactions are discussed. It is concluded that the formation of triazinic, imidazolic, and pyrimidinic compds. from pyrroles and carbonylisoxazoles is a synthesis of general application which involves the initial formation of simple mol. fragments (BzH, HN:CPhNH2, etc.), the identification of which indicates that the heterocyclic compds. first undergo oxidation, hydrolysis, and aminolysis.

=>
=>

=> d bib abs hitstr l20 retable

L20 ANSWER 1 OF 2 HCAPLUS COPYRIGHT 2002 ACS
AN 2001:752300 HCAPLUS
DN 136:48571
TI Neoceptor concept based on molecular complementarity in GPCRs: A mutant adenosine A3 receptor with selectively enhanced affinity for amine-modified nucleosides
AU Jacobson, Kenneth A.; Gao, Zhan-Guo; Chen, Aishe; Barak, Dov; Kim, Soon-Ai; Lee, Kyeong; Link, Andreas; Van Rompaey, Philippe; van Calenbergh, Serge; Liang, Bruce T.
CS Molecular Recognition Section Laboratory of Bioorganic Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases National Institutes of Health, Bethesda, MD, 20892, USA
SO Journal of Medicinal Chemistry (2001), 44(24), 4125-4136
CODEN: JMCMAR; ISSN: 0022-2623
PB American Chemical Society
DT Journal
LA English
AB Adenosine A3 receptors are of interest in the treatment of cardiac ischemia, inflammation, and neurodegenerative diseases. In an effort to create a unique receptor mutant that would be activated by tailor-made synthetic ligands, we mutated the human A3 receptor at the site of a crit. His residue in TM7, previously proposed to be involved in ligand recognition through interaction with the ribose moiety. The H272E mutant receptor displayed reduced affinity for most of the uncharged A3 receptor agonists and antagonists examd. For example, the nonselective agonist 1a was 19-fold less potent at the mutant receptor than at the wild-type receptor. The introduction of an amino group on the ribose moiety of adenosine resulted in either equipotency or enhanced binding affinity at the H272E mutant relative to wild-type A3 receptors, depending on the position of the amino group. 3'-Amino-3'-deoxyadenosine proved to be 7-fold more potent at the H272E mutant receptor than at the wild-type receptor, while the corresponding 2'- and 5'-amino analogs did not display significantly enhanced affinities. An 3'-amino-N6-iodobenzyl analog showed only a small enhancement at the mutant (Ki = 320 nM) vs wild-type receptors. The 3'-amino group was intended for a direct electrostatic interaction with the neg. charged ribose-binding region of the mutant receptor, yet mol. modeling did not support this notion. This design approach is an example of engineering the structure of mutant receptors to recognize synthetic ligands for which they are selectively matched on the basis of mol. complementarity between the mutant receptor and the ligand. We have termed such engineered receptors "neoceptors", since the ligand recognition profile of such mutant receptors need not correspond to the

profile of the parent, native receptor.

IT **382156-70-9P**
RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
(mutant adenosine A3 receptor with selectively enhanced affinity for amine-modified nucleosides)

RN 382156-70-9 HCAPLUS

CN Adenosine, 3'-amino-3'-deoxy-N-[(3-iodophenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Abbracchio, M	1999	890	79	Ann N Y Acad Sci	HCAPLUS
Azhayev, A	1979	6	625	Nucleic Acids Res	MEDLINE
Chen, A	2001	284	596	Biochem Biophys Res	HCAPLUS
Cheng, Y	1973	22	3099	Biochem Pharmacol	HCAPLUS
Coward, P	1998	95	352	Proc Natl Acad Sci U	HCAPLUS
Downey, J	1992	2	170	Trends Cardiovasc Me	HCAPLUS
Elling, C	1995	374	74	Nature	HCAPLUS
Ely, S	1992	85	893	Circulation	MEDLINE
Feichtinger, K	1998	63	3804	J Org Chem	HCAPLUS
Fong, T	1994	269	14957	J Biol Chem	HCAPLUS
Gallo-Rodriguez, C	1994	37	636	J Med Chem	HCAPLUS
Gao, Z	2000	60	661	Biochem Pharmacol	HCAPLUS
Gao, Z	2001	59	76	Mol Pharmacol	HCAPLUS
Harvey, B	1999	73	6729	J Virol	HCAPLUS
Holst, B	2000	58	263	Mol Pharmacol	HCAPLUS
Horn, F	1998	26	277	Nucleic Acids Res	
Ijzerman, A	1996	310	269	Eur J Pharmacol	HCAPLUS
Jacobson, K	1995	20	689	Drugs Future	
Jacobson, K	1995	38	1720	J Med Chem	HCAPLUS
Jacobson, K	1998	19	184	Trends Pharmacol Sci	HCAPLUS
Jarvis, M	1989	251	888	J Pharmacol Exp Ther	HCAPLUS
Jiang, Q	1996	50	512	Mol Pharmacol	HCAPLUS
Kim, H	2001	44	3092	J Med Chem	HCAPLUS
Kim, J	1995	270	13987	J Biol Chem	HCAPLUS
Kowaluk, E	2000	9	551	Expert Opin Invest D	MEDLINE
Lee, K	2001	11	1333	Biorg Med Chem Lett	HCAPLUS
Lerman, B	1989	80	1536	Circulation	MEDLINE
Liang, B	1998	95	6995	Proc Natl Acad Sci U	HCAPLUS

Logeart, D	2000	11	1015	Human Gene Ther	HCAPLUS
Mack, C	1998	115	168	J Thorac Cardiovasc	HCAPLUS
Maillard, M	1994	83	46	J Pharm Pharmacol	HCAPLUS
Mitchell, C	1999	276	C659	Am J Physiol	HCAPLUS
Moro, S	1998	38	1239	J Chem Inf Comput Sc	HCAPLUS
Murry, C	1986	74	1124	Circulation	MEDLINE
Olah, M	1992	267	10764	J Biol Chem	HCAPLUS
Olah, M	1994	45	978	Mol Pharmacol	HCAPLUS
Ozols, A	1980	7	557	Synthesis	
Palczewski, K	2000	289	739	Science	HCAPLUS
Rivkees, S	1999	274	3617	J Biol Chem	HCAPLUS
Robins, M	1992	11	821	Nucleosides Nucleoti	HCAPLUS
Saxena, P	1997	355	295	Naunyn-Schmiedebergs	HCAPLUS
Schwabe, U	1980	313	179	Naunyn-Schmiedebergs	HCAPLUS
Shah, A	2000	101	408	Circulation	HCAPLUS
Singer, B	2001	15	A566	FASEB J	
Strickler, J	1996	98	1773	J Clin Invest	HCAPLUS
Svensson, E	1999	99	201	Circulation	MEDLINE
Townsend-Nicholson, A	1994	269	2373	J Biol Chem	HCAPLUS
Tripos Associates	1993			The program SYBYL 6.	
Tucker, A	1994	269	27900	J Biol Chem	HCAPLUS
van Calenbergh, S	1997	40	3765	J Med Chem	HCAPLUS
van Muijlwijk-Koezen, J	2000	43	2227	J Med Chem	HCAPLUS
van Rhee, A	1996	37	1	Drug Dev Res	HCAPLUS
van Tilburg, E	1999	42	1393	J Med Chem	HCAPLUS
Von Lubitz, D	1994	263	59	Eur J Pharmacol	HCAPLUS
Vorbruggen, H	1981	114	1234	Chem Ber	
Weiner, S	1986	7	230	J Comput Chem	HCAPLUS
Wiesner, J	1999	289	1669	J Pharmacol Exp Ther	HCAPLUS

=> d bib abs hitrn fhitstr l20 retable 2

L20 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2002 ACS
AN 2001:247348 HCAPLUS
DN 134:266520
TI Preparation of nucleosides as adenosine receptors, antidiabetics, enzyme inhibitors, and for the treatment of ischemia
IN **Masamune, Hiroko; Deninno, Michael Paul; Scott, Robert William**
PA **Pfizer Products Inc., USA**
SO PCT Int. Appl., 194 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2001023399	A1	20010405	WO 2000-IB1353	20000922
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1216257	A1	20020626	EP 2000-958949	20000922
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
BR 2000014384	A	20020702	BR 2000-14384	20000922
NO 2002001474	A	20020522	NO 2002-1474	20020325

PRAI US 1999-156828P P 19990930
WO 2000-IB1353 W 20000922
OS MARPAT 134:266520
GI



I

AB Nucleosides I were prepd. as adenosine receptors, antidiabetics, enzyme inhibitors, and for the treatment of ischemia, wherein X is oxy, methylene or thio; Y is CH or N; Z is H, alkyl, alkyloxy, trifluoromethyl or halo; R1 is hydroxymethyl, alkoxymethyl, cycloalkoxymethyl, carboxy, alkoxycarbonyl, cycloalkoxycarbonyl, 1,1-aminoiminomethyl, 1,1-(mono-N- or di-N,N- alkylamino)iminomethyl, 1,1-(mono-N- or di-N,N-cycloalkylamino)iminomethyl, carbamoyl, mono-N- or di-N,N-alkylaminocarbonyl, mono-N- or di-N,N- cycloalkylaminocarbonyl or N-alkyl-N-cycloalkylaminocarbonyl; R2 is H, alkyl or cycloalkyl; R3 is halo, trifluoromethyl, cyano, alkyl, alkyloxy, ethenyl or ethynyl; D is oxy, thio, NH, alkyloxy, alkylthio or alkylamino; G is a partially satd., fully satd. or fully unsatd. five to eight membered ring optionally having one to three heteroatoms selected independently from oxygen, sulfur and nitrogen, or, a bicyclic ring consisting of two fused partially satd., fully satd. or fully unsatd. three to six membered rings, taken independently, optionally having one to four heteroatoms selected independently from nitrogen, sulfur and oxygen; wherein said G is optionally mono, di- or trisubstituted independently with halo, alkyl, trifluoromethyl, trifluoromethoxy, nitro, cyano, cycloalkyl, hydroxy or alkoxy or G is cyano, alkoxycarbonyl, cycloalkoxycarbonyl, amide, thioamide, alkylamine, cycloalkylamine. A3 agonists, methods of using such A3 agonists and pharmaceutical compns. contg. such A3 agonists. The A3 agonists are useful for the redn. of tissue damage resulting from tissue ischemia or hypoxia. Thus, [1-(8-bromoquinolin-5-yl)-5-cyclopropyl-1H-pyrazole-4-carbonyl]guanidine was prepd. for the treatment of ischemia.

IT **331730-00-8P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(prepn. of nucleosides as adenosine receptors antidiabetics enzyme inhibitors and for the treatment of ischemia)

IT **331727-55-0P 331727-57-2P 331727-58-3P**
331727-59-4P 331727-60-7P 331727-61-8P
331727-62-9P 331727-63-0P 331727-64-1P
331727-65-2P 331727-66-3P 331727-67-4P
331727-68-5P 331727-69-6P 331727-70-9P
331727-71-0P 331727-72-1P 331727-73-2P

331727-74-3P 331727-75-4P 331727-76-5P
331727-77-6P 331727-78-7P 331727-79-8P
331727-80-1P 331727-81-2P 331727-83-4P
331727-84-5P 331727-86-7P 331727-88-9P
331727-90-3P 331727-92-5P 331727-94-7P
331727-96-9P 331727-98-1P 331728-02-0P
331728-03-1P 331728-04-2P 331728-05-3P
331728-06-4P 331728-07-5P 331728-08-6P
331728-09-7P 331728-10-0P 331728-11-1P
331728-12-2P 331728-13-3P 331728-14-4P
331728-15-5P 331728-16-6P 331728-17-7P
331728-18-8P 331728-19-9P 331728-20-2P
331728-21-3P 331728-22-4P 331728-23-5P
331728-24-6P 331728-25-7P 331728-26-8P
331728-27-9P 331728-28-0P 331728-29-1P
331728-30-4P 331728-31-5P 331728-32-6P
331728-33-7P 331728-34-8P 331728-35-9P
331728-36-0P 331728-37-1P 331728-38-2P
331728-39-3P 331728-40-6P 331728-41-7P
331728-42-8P 331728-43-9P 331728-45-1P
331728-46-2P 331728-47-3P 331728-48-4P
331728-49-5P 331728-50-8P 331728-51-9P
331728-52-0P 331728-53-1P 331728-54-2P
331728-55-3P 331728-56-4P 331728-57-5P
331730-01-9P 331730-02-0P 331825-98-0P
331825-99-1P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); IMF (Industrial manufacture); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of nucleosides as adenosine receptors antidiabetics enzyme inhibitors and for the treatment of ischemia)

IT **331728-59-7 331728-61-1 331728-62-2**
RL: RCT (Reactant); RACT (Reactant or reagent)
(prepn. of nucleosides as adenosine receptors antidiabetics enzyme inhibitors and for the treatment of ischemia)

IT **331728-58-6P 331728-60-0P 331728-63-3P**
331728-64-4P 331728-65-5P 331728-67-7P
331728-68-8P 331728-69-9P 331728-70-2P
331728-71-3P 331728-72-4P 331728-73-5P
331728-74-6P 331728-75-7P 331728-76-8P
331728-77-9P 331728-78-0P 331728-79-1P
331728-80-4P 331728-81-5P 331728-82-6P
331728-83-7P 331728-88-2P 331728-89-3P
331728-90-6P 331728-91-7P 331728-92-8P
331728-93-9P 331728-94-0P 331728-95-1P
331728-96-2P 331728-97-3P 331728-98-4P
331728-99-5P 331729-00-1P 331729-01-2P
331729-02-3P 331729-99-8P 331826-00-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of nucleosides as adenosine receptors antidiabetics enzyme inhibitors and for the treatment of ischemia)

IT **331730-00-8P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(prepn. of nucleosides as adenosine receptors antidiabetics enzyme inhibitors and for the treatment of ischemia)

RN 331730-00-8 HCAPLUS
CN .beta.-D-Ribofuranuronic acid, 3-amino-1-[6-[[[5-chloro-2-[(3-methyl-5-isoxazolyl)methoxy]phenyl]methyl]amino]-9H-purin-9-yl]-1,3-dideoxy- (9CI)

(CA INDEX NAME)

Absolute stereochemistry.



RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Anon	1993			CA 2113547 A	HCAPLUS
Anon	1993			AU 4061293 A	
Anon	1993			WO 9323418 A	HCAPLUS
Anon	1994			EP 0603348 A	HCAPLUS
Anon	1994			JP 65-08855 T	
Anon	1994			NO 940123 A	
Anon	1994			FI 940167 A	
Anon	1995			AU 7331094 A	
Anon	1995			WO 9502604 A	HCAPLUS
Anon	1996			EP 0708781 A	HCAPLUS
Anon	1996			NZ 252110 A	
Anon	1996			AU 671995 B	HCAPLUS
Anon	1997			US 5688774 A	HCAPLUS
Anon	1998			IL 105673 A	HCAPLUS
Anon	1998			US 5773423 A	HCAPLUS
Gallo-Rodriguez, C	1994	37	636	Journal of Medicinal	HCAPLUS
Novonordisk AS	1993			WO 9323418 A	HCAPLUS
US Government	1995			WO 9502604 A	HCAPLUS
Yamashita, M	1984	25	4689	Tetrahedron Letters	HCAPLUS

=> fil reg
FILE 'REGISTRY' ENTERED AT 15:40:54 ON 07 AUG 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

STRUCTURE FILE UPDATES: 5 AUG 2002 HIGHEST RN 442625-99-2
DICTIONARY FILE UPDATES: 5 AUG 2002 HIGHEST RN 442625-99-2

TSCA INFORMATION NOW CURRENT THROUGH January 7, 2002

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Calculated physical property data is now available. See HELP PROPERTIES for more information. See STNote 27, Searching Properties in the CAS Registry File, for complete details:
http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf

=> d l12 ide can 1 10 20 30 40 50 60 70 80 90 100 110 120 130 137

L12 ANSWER 1 OF 137 REGISTRY COPYRIGHT 2002 ACS
RN 331826-00-7 REGISTRY
CN Hexopyranose, 6-O-[2-[[[9-(3-azido-3-deoxy-N-methyl-.beta.-D-ribofuranuronamidosyl)-9H-purin-6-yl]amino]methyl]-4-chlorophenyl]-1,2:3,4-bis-O-(1-methylethylidene)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C30 H36 Cl N9 O9
SR CA
LC STN Files: CA, CAPLUS

Absolute stereochemistry.



1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 134:266520

L12 ANSWER 10 OF 137 REGISTRY COPYRIGHT 2002 ACS
RN 331729-00-1 REGISTRY
CN .beta.-D-Ribofuranuronamide, 3-azido-1-[6-[[[5-chloro-2-[(4-methyl-1,2,3-thiadiazol-5-yl)methoxy]phenyl]methyl]amino]-9H-purin-9-yl]-1,3-dideoxy-N-methyl- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C22 H22 Cl N11 O4 S
SR CA
LC STN Files: CA, CAPLUS

Absolute stereochemistry.



1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 134:266520

L12 ANSWER 20 OF 137 REGISTRY COPYRIGHT 2002 ACS
RN 331728-90-6 REGISTRY
CN .beta.-D-Ribofuranuronamide, 3-azido-1-[6-[[[5-chloro-2-[[(3S)-tetrahydro-3-furanyl]methoxy]phenyl]methyl]amino]-9H-purin-9-yl]-1,3-dideoxy-N-methyl- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C23 H26 Cl N9 O5
SR CA
LC STN Files: CA, CAPLUS

Absolute stereochemistry.



1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 134:266520

L12 ANSWER 30 OF 137 REGISTRY COPYRIGHT 2002 ACS
RN 331728-76-8 REGISTRY
CN .beta.-D-Ribofuranuronamide, 3-azido-1-[6-[[[5-chloro-2-[(2-methylphenyl)methoxy]phenyl]methyl]amino]-9H-purin-9-yl]-1,3-dideoxy-N-methyl- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C26 H26 Cl N9 O4
SR CA
LC STN Files: CA, CAPLUS

Absolute stereochemistry.



1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 134:266520

L12 ANSWER 40 OF 137 REGISTRY COPYRIGHT 2002 ACS
RN 331728-65-5 REGISTRY
CN .beta.-D-Ribofuranuronamide, 3-azido-1-[6-[[[5-chloro-2-[2-(4-morpholinyl)ethoxy]phenyl]methyl]amino]-9H-purin-9-yl]-1,3-dideoxy-N-methyl- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C24 H29 Cl N10 O5
SR CA
LC STN Files: CA, CAPLUS

Absolute stereochemistry.



1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 134:266520

L12 ANSWER 50 OF 137 REGISTRY COPYRIGHT 2002 ACS
RN 331728-55-3 REGISTRY
CN .beta.-D-Ribofuranuronamide, 3-amino-1-[6-[[[2-(2-[1,4'-bipiperidin]-1'-yl-2-oxoethoxy)-5-chlorophenyl]methyl]amino]-9H-purin-9-yl]-1,3-dideoxy-N-methyl- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C30 H40 Cl N9 O5
SR CA
LC STN Files: CA, CAPLUS

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 134:266520\

L12 ANSWER 60 OF 137 REGISTRY COPYRIGHT 2002 ACS
RN 331728-45-1 REGISTRY
CN .beta.-D-Ribofuranuronamide, 3-amino-1-[2-chloro-6-[[[5-chloro-2-(phenylmethoxy)phenyl]methyl]amino]-9H-purin-9-yl]-1,3-dideoxy-N-methyl- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C25 H25 Cl2 N7 O4
SR CA
LC STN Files: CA, CAPLUS

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 134:266520

L12 ANSWER 70 OF 137 REGISTRY COPYRIGHT 2002 ACS
RN 331728-34-8 REGISTRY
CN .beta.-D-Ribofuranuronamide, 3-amino-1-[6-[[[5-chloro-2-[2-oxo-2-(4-tricyclo[3.3.1.13,7]dec-2-yl-1-piperazinyl)ethoxy]phenyl]methyl]amino]-9H-purin-9-yl]-1,3-dideoxy-N-methyl- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C34 H44 Cl N9 O5
SR CA
LC STN Files: CA, CAPLUS

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 134:266520

L12 ANSWER 80 OF 137 REGISTRY COPYRIGHT 2002 ACS
RN 331728-24-6 REGISTRY
CN .beta.-D-Ribofuranuronamide, 3-amino-1-[6-[[[5-chloro-2-[2-(4-cyclopentyl-1-piperazinyl)-2-oxoethoxy]phenyl]methyl]amino]-9H-purin-9-yl]-1,3-dideoxy-N-methyl- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C29 H38 Cl N9 O5
SR CA
LC STN Files: CA, CAPLUS

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 134:266520

L12 ANSWER 90 OF 137 REGISTRY COPYRIGHT 2002 ACS
RN 331728-14-4 REGISTRY
CN .beta.-D-Ribofuranuronamide, 3-amino-1-[6-[[[2-[2-(1-azetidinyl)-2-oxoethoxy]-5-chlorophenyl]methyl]amino]-9H-purin-9-yl]-1,3-dideoxy-N-methyl- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C23 H27 Cl N8 O5
SR CA
LC STN Files: CA, CAPLUS

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 134:266520

L12 ANSWER 100 OF 137 REGISTRY COPYRIGHT 2002 ACS
RN 331728-04-2 REGISTRY
CN Acetic acid, [2-[[[9-(3-amino-3-deoxy-N-methyl-.beta.-D-ribofuranuronamidosyl)-9H-purin-6-yl]amino]methyl]-4-chlorophenoxy]- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C20 H22 Cl N7 O6
SR CA
LC STN Files: CA, CAPLUS

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 134:266520

L12 ANSWER 110 OF 137 REGISTRY COPYRIGHT 2002 ACS
RN 331727-84-5 REGISTRY
CN .beta.-D-Ribofuranuronamide, 3-amino-1-[6-[[[5-chloro-2-(5-isothiazolylmethoxy)phenyl]methyl]amino]-9H-purin-9-yl]-1,3-dideoxy-N-methyl- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C22 H23 Cl N8 O4 S
SR CA
LC STN Files: CA, CAPLUS

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 134:266520

L12 ANSWER 120 OF 137 REGISTRY COPYRIGHT 2002 ACS
RN 331727-73-2 REGISTRY
CN .beta.-D-Ribofuranuronamide, 3-amino-1-[6-[[[5-chloro-2-[[3-[2-(4-morpholinyl)ethoxy]phenyl]methoxy]phenyl]methyl]amino]-9H-purin-9-yl]-1,3-dideoxy-N-methyl- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C31 H37 Cl N8 O6
SR CA
LC STN Files: CA, CAPLUS

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

NHMe

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 134:266520

L12 ANSWER 130 OF 137 REGISTRY COPYRIGHT 2002 ACS
RN 331727-63-0 REGISTRY
CN .beta.-D-Ribofuranuronamide, 3-amino-1-[6-[[[5-chloro-2-[(4-chlorophenyl)methoxy]phenyl]methyl]amino]-9H-purin-9-yl]-1,3-dideoxy-N-methyl- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C25 H25 Cl2 N7 O4
SR CA
LC STN Files: CA, CAPLUS

Absolute stereochemistry. Rotation (-).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)

1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 134:266520

L12 ANSWER 137 OF 137 REGISTRY COPYRIGHT 2002 ACS
RN 331727-55-0 REGISTRY
CN .beta.-D-Ribofuranuronamide, 3-amino-1-[6-[[[5-chloro-2-[(3-methyl-5-isoxazolyl)methoxy]phenyl]methyl]amino]-9H-purin-9-yl]-1,3-dideoxy-N-methyl- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C23 H25 Cl N8 O5
SR CA
LC STN Files: CA, CAPLUS

Absolute stereochemistry. Rotation (-).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 134:266520

=> d ide can tot 134

L34 ANSWER 1 OF 5 REGISTRY COPYRIGHT 2002 ACS
RN 331727-80-1 REGISTRY
CN .beta.-D-Ribofuranuronamide, 3-amino-1-[6-[[[5-chloro-2-(2-thiazolylmethoxy)phenyl]methyl]amino]-9H-purin-9-yl]-1,3-dideoxy-N-methyl- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF **C22 H23 Cl N8 O4 S**
SR CA
LC STN Files: CA, CAPLUS

Absolute stereochemistry. Rotation (-).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 134:266520

L34 ANSWER 2 OF 5 REGISTRY COPYRIGHT 2002 ACS
RN 331727-76-5 REGISTRY
CN .beta.-D-Ribofuranuronamide, 3-amino-1-[6-[[[5-chloro-2-(2-furanylmethoxy)phenyl]methyl]amino]-9H-purin-9-yl]-1,3-dideoxy-N-methyl- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF **C23 H24 Cl N7 O5**
SR CA
LC STN Files: CA, CAPLUS

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 134:266520

L34 ANSWER 3 OF 5 REGISTRY COPYRIGHT 2002 ACS
RN 331727-70-9 REGISTRY
CN .beta.-D-Ribofuranuronamide, 3-amino-1-[6-[[[5-chloro-2-(3-furanylmethoxy)phenyl]methyl]amino]-9H-purin-9-yl]-1,3-dideoxy-N-methyl- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF **C23 H24 Cl N7 O5**
SR CA
LC STN Files: CA, CAPLUS

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 134:266520

L34 ANSWER 4 OF 5 REGISTRY COPYRIGHT 2002 ACS
RN 331727-57-2 REGISTRY
CN .beta.-D-Ribofuranuronamide, 3-amino-1-[6-[[[5-chloro-2-(phenylmethoxy)phenyl]methyl]amino]-9H-purin-9-yl]-1,3-dideoxy-N-methyl- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF **C25 H26 Cl N7 O4**
SR CA
LC STN Files: CA, CAPLUS

Absolute stereochemistry. Rotation (-).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 134:266520

L34 ANSWER 5 OF 5 REGISTRY COPYRIGHT 2002 ACS
RN 331727-55-0 REGISTRY
CN .beta.-D-Ribofuranuronamide, 3-amino-1-[6-[[[5-chloro-2-[(3-methyl-5-isoxazolyl)methoxy]phenyl]methyl]amino]-9H-purin-9-yl]-1,3-dideoxy-N-methyl- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF **C23 H25 Cl N8 O5**
SR CA
LC STN Files: CA, CAPLUS

Absolute stereochemistry. Rotation (-).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

```
              1 REFERENCES IN FILE CA (1967 TO DATE)
              1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE   1:  134:266520


=> d his

     (FILE 'HOME' ENTERED AT 15:24:56 ON 07 AUG 2002)
                SET COST OFF

     FILE 'REGISTRY' ENTERED AT 15:25:13 ON 07 AUG 2002
L1                STR
L2              4 S L1
L3                STR L1
L4              4 S L3
L5                STR L3
L6                STR L5
L7              9 S L6
L8            267 S L6 FUL
                  SAV L8 CRANE640/A
L9                STR L6
L10           142 S L9 FUL SUB=L8
                  SAV L10 CRANE640A/A
L11               STR L1
L12           137 S L11 FUL SUB=L10
                  SAV L12 CRANE640B/A
L13             5 S L10 NOT L12
L14             2 S L13 AND (C17H20N6O3 OR C17H19IN6O3)
L15           139 S L12,L14

     FILE 'HCAOLD' ENTERED AT 15:34:01 ON 07 AUG 2002
L16             5 S L15

     FILE 'HCAPLUS' ENTERED AT 15:34:13 ON 07 AUG 2002
L17             2 S L15
L18             1 S L17 AND (DENINNO M? OR DE NINNO M? OR MASAMUNE H? OR SCOTT R?
L19             1 S L17 AND PFIZER?/PA,CS
L20             2 S L17-L19

     FILE 'USPATFULL, USPAT2' ENTERED AT 15:36:32 ON 07 AUG 2002
L21             0 S L15

     FILE 'REGISTRY' ENTERED AT 15:36:45 ON 07 AUG 2002
L22             1 S L15 AND CAOLD/LC

     FILE 'HCAOLD' ENTERED AT 15:36:58 ON 07 AUG 2002
                SEL AN L16 1-5
                EDIT /AN /OREF

     FILE 'HCAPLUS' ENTERED AT 15:37:33 ON 07 AUG 2002
L23             8 S E1-E5
L24             5 S L23 NOT (YOSHID ? OR CASTELLANI ? OR ANGIER ?)/AU

     FILE 'REGISTRY' ENTERED AT 15:39:22 ON 07 AUG 2002

     FILE 'HCAOLD' ENTERED AT 15:39:37 ON 07 AUG 2002

     FILE 'HCAPLUS' ENTERED AT 15:39:47 ON 07 AUG 2002

     FILE 'REGISTRY' ENTERED AT 15:40:54 ON 07 AUG 2002
L25             2 S L22,L14
```

L26	127	S	L15 AND CL/ELS
L27	90	S	L26 AND 5/NR
L28	83	S	L27 AND 1/CL
L29	2	S	L28 AND C22H23CLN8O4S
L30	1	S	L29 AND NCSC2/ES
L31	1	S	L28 AND C23H25CLN8O5
L32	1	S	L28 AND C25H26CLN7O4
L33	2	S	L28 AND C23H24CLN7O5
L34	5	S	L30-L33